News | CCA | The Latest Of The Cloud Communications Industry

Cooley: #1 in US for IPOs by Operating Companies Year-to-Date

Written by Amy Ralls | May 1, 2020 4:00:00 AM
Firm also advised on all three operating company IPOs priced thus far in April Palo Alto – April 27, 2020 – Cooley’s capital markets practice continues to lead the nation in partnering with innovative companies and their investment banks through the IPO process, despite the numerous challenges faced in light of the COVID-19 pandemic. From the start of the year, Cooley is the #1 law firm nationwide for IPOs by US operating companies and is also the #1 law firm nationwide for IPOs by life sciences companies. Three IPOs by operating companies have priced in the US during the month of April to-date – Cooley has advised on all of them. They include: Keros Therapeutics’ $110.4 million IPO of 6,900,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Keros’ securities now trade on the Nasdaq Global Market under the symbol “KROS.” The underwriters for Zentalis Pharmaceuticals’ $190 million IPO of 10,557,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Zentalis’ securities now trade on the Nasdaq Global Market under the symbol “ZNTL.” The underwriters for ORIC Pharmaceuticals’ $138 million IPO of 8,625,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. ORIC’s securities now trade on the Nasdaq Global Select Market under the symbol “ORIC.” Additionally, Cooley advised on numerous recent notable securities transactions involving already public issuers – either on the company- or bank-side – including Shake Shack’s $140 million public offering of Class A common stock and $75 million “at-the-market” equity offering program,  NVIDIA’s $5 billion investment grade note offering, Health Catalyst’s $260 million convertible senior notes offering, Invitae’s $184 million public offering of common stock, Immunovant’s $139.4 million public offering of common stock and Crinetics’ $115.1 million public offering of common stock. Cooley has been the #1 law firm advising companies going public across all industries since 2014 and the #1 law firm for all venture-backed IPOs across all industries for 15+ years, according to IPO Vital Signs and PitchBook. This year, the firm earned a  three-time Capital Markets Practice Group of the Year distinction by Law360 and was named one of the decade's top IPO legal advisors by Bloomberg Law. About Cooley LLP Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.